When was BCAL Diagnostics founded?

BCAL Diagnostics was founded in 2010.

Where is BCAL Diagnostics located?

BCAL Diagnostics is headquartered in Sydney, Australia.

How many employees does BCAL Diagnostics have?

As of Jun 30, 2026, the latest employee count at BCAL Diagnostics is 21.

Where does BCAL Diagnostics rank among its competitors?

BCAL Diagnostics ranks 57th amongst 85 active competitors, of which 37 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Mammogen, which secured $30M in Jun, 2026.

Who are the top competitors of BCAL Diagnostics?

BCAL Diagnostics' top competitors include ScreenPoint, PreludeDx and Syantra Health. Among them, Mammogen secured the most recent funding round in June, 2026.

BCAL Diagnostics - 2026 Company Profile, Team, Funding & Competitors

BCAL Diagnostics is a public company based in Sydney (Australia), founded in 2010 by Jayne shaw. It operates as a Breast cancer screening test. The company has 85 active competitors, including 37 funded and 10 that have exited. Its top competitors include companies like ScreenPoint, PreludeDx and Syantra Health.

Company Details

BCAL Diagnostics is dedicated towards development of a novel lipid biomarker blood test for early detection of breast cancer. Its flagship product "BCAL test (Breast Cancer Associated Lipids test)" is a blood test for detection of cancer-associated lipid biomarkers. The test will be less invasive and will help patients in avoiding unnecessary x-rays exposure. The company has published an article "Circulating Phospholipids as Biomarkers of Breast Cancer: a review” to explain the theory behind the BCAL Dx technology. In collaboration with the US researchers, the company did a small validation 200-patient study to reaffirm the results of its preliminary study indications of around 90% accuracy.

Website: bcaldiagnostics.com
Social
Email ID: *****@bcaldiagnostics.com

Key Metrics

Founded Year

2010

Location

Sydney, Australia

Stage

Public

Investors

Cicada Innovations

Ranked

57^th among 85 active competitors

Employee Count

21 as on Jun 30, 2026

Similar Companies

ScreenPoint & 121 more

Exit Details

Public

View BCAL Diagnostics' full profile

BCAL Diagnostics got listed on Jul 21, 2021.

Click here to take a look at BCAL Diagnostics's IPO in detail

BCAL Diagnostics is a funded company. BCAL Diagnostics has 1 institutional investor.

View details of BCAL Diagnostics's funding rounds and investors

The founders of BCAL Diagnostics is Jayne shaw.

Here are the details of BCAL Diagnostics' key team members:

Jayne shaw: Co-Founder of BCAL Diagnostics.

View details of BCAL Diagnostics's Founder profiles and Board Members

BCAL Diagnostics' employee count trend

BCAL Diagnostics has 21 employees as of Jun 26. Here is BCAL Diagnostics's employee count trend over the years:

Employee count trend for BCAL Diagnostics

Uncover BCAL Diagnostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BCAL Diagnostics include ScreenPoint, PreludeDx and Syantra Health. Here is the list of Top 10 competitors of BCAL Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ScreenPoint 2014, Nijmegen (Netherlands), Series C	Developer of artificial intelligence software for analyzing breast imaging mammograms	$47M	Insight Partners, Siemens & 3 others	63/100
2nd	PreludeDx 2009, Laguna Hills (United States), Series B	Provider of risk assessment test for early stage breast cancer	$51.7M	Evidity Health Capital, GenesisCare & 2 others	57/100
3rd	Syantra Health 2013, Calgary (Canada), Series A	Developer of a blood test device to detect breast cancer	$10.4M	Accelerate Fund, Plug and Play Tech Center ... & 5 others	54/100
4th	Curasight 2013, Copenhagen (Denmark), Series A	Developer of PET ligands for breast cancer indications	$11.5M	PreSeed Ventures	53/100
5th	Mammogen 2020, Aliso Viejo (United States), Series A	Developer of a diagnostic test to detect breast cancer	$32M	-	49/100
6th	Isotropic Imaging 2016, Las Vegas (United States), Public	Innovating breast cancer imaging with dedicated 3D breast CT technology	-	-	48/100
7th	Devicor Medical 1959, Cincinnati (United States), Acquired	Advancing breast care through innovative diagnostic and surgical solutions	$14M	-	48/100
8th	OncoStem 2011, Bengaluru (India), Series A	Developer of prognostic tests for the detection of cancer	$9M	Artiman, Peak XV Partners & 1 others	45/100
9th	Biotheranostics 2008, San Diego (United States), Acquired	Commercial stage molecular diagnostics tests tailored to individual cancer patients.	$32M	MVM, Health Quest Capital & 2 others	44/100
10th	RNA Diagnostics 2010, Toronto (Canada), Series A	Developer of diagnostic assays for the detection of cancer	$13.8M	iGan Partners, BDC & 4 others	41/100
57th	BCAL Diagnostics 2010, Sydney (Australia), Public	Breast cancer screening test	-	Cicada Innovations	24/100